Pliant Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.17 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.05Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $65M Enterprise Value $40.1M Shares Outstanding 61.9M diluted Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Pliant Therapeutics is undergoing a major strategic transition following the termination of its lead program, bexotegrast, in idiopathic pulmonary fibrosis (IPF) in early 2025 due to safety concerns. This setback led to a 45% workforce reduction to preserve capital. The company's primary focus has shifted to its oncology candidate, PLN-101095, a dual selective inhibitor of ΑvΒ8 and ΑvΒ1 integrins, currently in the Phase 1b FORTIFY trial for checkpoint-refractory solid tumors. While early Phase 1a data showed encouraging anti-tumor activity, the pipeline is early-stage, and near-term catalysts are limited. However, with a solid cash runway extending into the second half of 2028 ($172.4M as of Q1 2026) and a disciplined cost structure, the downside is protected, making it a Hold pending further clinical validation of its oncology platform. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$2.00 Mean target$2.50 High · most bullish analyst$3.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.5020% PLN-101095 fails to show meaningful clinical benefit or encounters safety hurdles in the Phase 1b trial, leading to program delays or termination. The cash runway is depleted faster than expected, forcing highly dilutive capital raises at depressed valuations. Base CaseCentral scenario $1.6650% PLN-101095 shows acceptable safety and moderate efficacy in the FORTIFY trial, with interim data in 2027 supporting continued development. Bexotegrast development in PSC remains slow but steady. The company maintains its disciplined spending, preserving its cash runway into 2028 without significant dilution. Bull CaseUpside scenario $3.0030% PLN-101095 demonstrates exceptional efficacy in the Phase 1b FORTIFY trial, showing high objective response rates in checkpoint-refractory solid tumors. This validates Pliant's integrin platform in oncology, attracting a major pharmaceutical partner and driving a significant upward re-rating of the stock. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |